穿心莲内酯对慢阻肺疾病急性加重期患者的影响

doi:10.3969/j.issn.1000-8535.2022.01.002

摘要/Abstract

摘要： 目的本文旨在研究穿心莲内酯对慢性阻塞性肺疾病急性加重期(acute exacerbation of chronic obstructive pulmonary disease,AECOPD)患者血清学中的炎症反应因子及肺部功能改变的影响。方法从我院已出院的患者中挑选2017年6月—2018年6月期间收治的AECOPD患者共80例,其中给予哌拉西林舒巴坦抗感染和雾化吸入布地奈德及复方异丙托溴铵治疗的患者为对照组,对照组的治疗方法基础上给予喜炎平注射液的患者为观察组,各40例。对2组患者接受治疗前后血清学中的基质金属蛋白酶-9 (matrix metalloproteinase-9, MMP-9)、降钙素原 (procalcitonin, PCT)、白介素-6 (interleukin-6, IL-6) 水平和肺功能指标等方面进行比较。结果 2组治疗前血清学MMP-9、PCT、IL-6和肺功能指标第1秒用力呼气容积(forced expiratory volume in one second, FEV1)、用力肺活量(forced vital capacity, FVC)、一秒率(FEV1/FVC)无差异(P＞0.05)。观察组经过治疗后MMP-9为(1995.13±347.281)pg/mL、IL-6为(7.98±3.23)pg/mL,低于对照组的(2159.30±367.477)pg/mL、(10.03±5.45)pg/mL(P＜0.05);观察组治疗后的PCT、FEV1、FVC和FEV1/FVC与对照组相比差异无统计学意义 (P＞0.05)。结论穿心莲内酯在AECOPD患者中可以减少血清学中炎症因子,值得在临床中推广。

关键词: 穿心莲内酯, 慢性阻塞性肺疾病急性加重期, 炎症因子, 肺功能

Abstract: Objective To investigate the effect of andrographolide on levels of serum inflammatory factors and pulmonary function in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods Eighty patients with AECOPD who were treated in our hospital from June 2017 to June 2018 were selected. Forty patients in the control group were given anti-infection treatment with piperacillin and sulbactam and aerosol inhalation with compound ipratropium bromide and budesonide, while other 40 patients in study group were given andrographolide additionally. The levels of serum matrix metalloproteinase-9 (MMP-9), procalcitonin (PCT), interleukin-6 (IL-6) and the pulmonary function indexes of patients in the two groups were observed and compared before and after treatment. Results There were no statistically significant differences in the serum levels of MMP-9, PCT and IL-6 and the pulmonary function indexes forced expiratory volume in one second (FEV1), forced vital capacity (FVC) and FEV1/FVC of the two groups before treatment (P>0.05). After treatment, in the study group, the MMP-9 and IL-6 levels in serum were (1995.13±347.281)pg/mL and (7.98±3.23)pg/mL respectively, which were significantly lower than that in the control group [(2159.30±367.477) pg/mL and (10.03±5.45) pg/mL (P＜0.05)].Compared with the control group, differences in the PCT, FEV1, FVC and FEV1/FVC in the study group were not statistically significant (P>0.05). Conclusion Andrographolide had significant clinical effect on the treatment of AECOPD, which could reduce the levels of serum inflammatory factors and it is worthy of clinical application.

Key words: andrographolide, acute exacerbation of chronic obstructive pulmonary disease, inflammatory factors, pulmonary function

谢健, 邓淑妍, 李学莹, 屈桂妮, 彭晓青. 穿心莲内酯对慢阻肺疾病急性加重期患者的影响[J]. 广州医药, 2022, 53(1): 6-11.

XIE Jian, DENG Shuyan, LI Xueying, QU Guini, PENG Xiaoqing. Impact of andrographolide in patients with acute exacerbation of chronic obstructive pulmonary disease[J]. Guangzhou Medical Journal, 2022, 53(1): 6-11.

参考文献

[1] WANG C, XU J, YANG L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health[CPH] study): a national cross-sectional study[J]. Lancet, 2018, 391(10131): 1706-1717.
[2] 新型冠状病毒感染的肺炎诊疗方案(第六版试行)[S]. 国家卫生健康委办公厅,2020.
[3] SORIANO J B, ABAJOBIR A A, ABATEK H, et al. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015[J]. Lancet Respir Med, 2017, 5(9): 691-706.
[4] CHAUDHURI R, MCSHARRY C, BRADY J, et al. Low sputum MMP-9/TIMP ratio is associated with airway narrowing in smokers with asthma[J]. Eur Respir J, 2014, 44(4):895-904.
[5] WOODE D, SHIOMI T, D'ARMIENTO J. Collagenolytic matrix metalloproteinases in chronic obstructive lung disease and cancer[J]. Cancers, 2015, 7(1): 329-341.
[6] PAPAKONSTANTINOU E, KARAKIULAKIS G, BATZIOS S, et al. Acute exacerbations of COPD are associated with significant activation of matrix metalloproteinase 9 irrespectively of airway obstruction, emphysema and infection[J]. Respir Res, 2015, 16(1): 78.
[7] LINDER R, ROMMARK E, POURAZAR J, et al. Serum metalloproteinase-9 is related to COPD severity and symptoms-cross-sectional data from a population based cohort-study[J]. Respir Res, 2015, 16(1): 28.
[8] RIEDEL S. Procalcitonin and the role of biomarkers in the diagnosis and management of sepsis[J]. Diagn Microbiol Infect Dis, 2012, 73(3): 221-227.
[9] SCHUETZ P, CHRIST-CRAIN M, THOMANN R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial[J]. JAMA, 2009, 302(10): 1059-1066.
[10] MÜLLER B, HARBARTH S, STOLZ D, et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia[J]. BMC Infect Dis, 2007, 7(1): 10.
[11] LIU H H, ZHANG M W, GUO J B, et al. Procalcitonin and C-reactive protein in early diagnosis of sepsis caused by either Gram-negative or Gram-positive bacteria[J]. Ir J Med Sci, 2017, 186(1): 207-212.
[12] LEE H. Procalcitonin as a biomarker of infectious diseases[J]. Korean J Intern Med, 2013, 28(3): 285.
[13] 王丽,谭焰,谷伟,等.慢性阻塞性肺病缓解期患者血清中TNF-α、IL-6和IL-8表达的研究[J].临床肺科杂志,2011,16(6):835-836.
[14] SINGH S, VERMA S K, KUMAR S, et al. Correlation of severity of chronic obstructive pulmonary disease with potential biomarkers[J]. Immunol Lett, 2018(196): 1-10.
[15] ANSARIN K, RASHIDI F, NAMDAR H, et al. Echocardiographic evaluation of the relationship between inflammatory factors (IL6, TNFα, hs-CRP) and secondary pulmonary hypertension in patients with COPD. A cross sectional study[J]. Pneumologia, 2015, 64(3): 31-35.
[16] HERESI G A, AYTEKIN M, HAMMEL J P, et al. Plasma interleukin-6 adds prognostic information in pulmonary arterial hypertension[J]. Eur Respir J, 2014, 43(3): 912-914.
[17] 郑劲平, 高怡. 肺功能检查实用指南[M]. 北京: 人民卫生出版社, 2009.
[18] VOGELMEIER C F, CRINER G J, MARTINEZ F J, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary[J]. Am J Respir Crit Care Med, 2017, 195(5): 557-582.
[19] LEE K C, CHANG H H, CHUNG Y H, et al. Andrographolide acts as an anti-inflammatory agent in LPS-stimulated RAW264.7 macrophages by inhibiting STAT3-mediated suppression of the NF-κB pathway[J]. J Ethnopharmacol, 2011, 135(3): 678-684.
[20] LI F, LI S. Effects of andrographolide on the activation of mitogen activated protein kinases and nuclear factor-κB in mouse peritoneal macrophage-derived foam cells[J]. Chin J Integr Med, 2012, 18(5): 391-394.
[21] CHEN H W, LIN A H, CHU H C, et al. Inhibition of TNF-α-induced inflammation by andrographolide via down-regulation of the PI3K/Akt signaling pathway[J]. J Nat Prod, 2011, 74(11): 2408-2413.
[22] BAO Z, GUAN S, CHENG C, et al. A novel antiinflammatory role for andrographolide in asthma via inhibition of the nuclear factor-κB pathway[J]. Am J Respir Crit Care Med, 2009, 179(8): 657-665.
[23] SOLER N, TORRES A, EWIG S, et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation[J]. Am J Respir Crit Care Med, 1998, 157(5): 1498-1505.
[24] WEDZICHA J A, SEEMUNGAL T A R. COPD exacerbations: defining their cause and prevention[J]. Lancet, 2007, 370(9589): 786-796.
[25] WHITE A J, GOMPERTZ S, STOCKLEY R A. Chronic obstructive pulmonary disease. 6: The aetiology of exacerbations of chronic obstructive pulmonary disease[J]. Thorax, 2003, 58(1): 73-80.
[26] ARIFULLAH M, NAMSA N D, MANDAL M, et al. Evaluation of anti-bacterial and anti-oxidant potential of andrographolide and echiodinin isolated from callus culture of Andrographis paniculata Nees[J]. Asian Pac J Trop Biomed, 2013, 3(8): 604-610.